Thanks for posting this.
I’m biased: for me the CGM was a complete game changer. So I thought the news summary of this research was a pretty tepid endorsement of the technology. The article itself provides a little more enthusiasm, but seems to be equally focused on the related but separate topic of hypoglycemia.
At the articles’ end, it talks about assessing the value of a CGM for clinical trials. Maybe that’s still an outstanding question, but to me it’s a no brainer – what trial wouldn’t benefit from having that data?